India markets close in 2 hours 50 minutes
  • BSE SENSEX

    52,180.26
    -164.19 (-0.31%)
     
  • Nifty 50

    15,632.15
    -51.20 (-0.33%)
     
  • USD/INR

    74.2700
    +0.1310 (+0.18%)
     
  • Dow

    33,290.08
    -533.32 (-1.58%)
     
  • Nasdaq

    14,030.38
    -131.02 (-0.93%)
     
  • BTC-INR

    2,461,658.75
    -173,510.50 (-6.58%)
     
  • CMC Crypto 200

    821.49
    -118.45 (-12.60%)
     
  • Hang Seng

    28,447.75
    -353.52 (-1.23%)
     
  • Nikkei

    28,010.93
    -953.15 (-3.29%)
     
  • EUR/INR

    88.1153
    +0.1447 (+0.16%)
     
  • GBP/INR

    102.4932
    +0.1372 (+0.13%)
     
  • AED/INR

    20.1630
    +0.0220 (+0.11%)
     
  • INR/JPY

    1.4779
    -0.0055 (-0.37%)
     
  • SGD/INR

    55.1520
    +0.0720 (+0.13%)
     

MediBuddy spreading awareness on PCOD, PCOS with digital campaign

·1-min read
One in every 10 women suffer from PCOD and PCOS
One in every 10 women suffer from PCOD and PCOS

Madurai (Tamil Nadu) [India], April 12 (ANI): Digital healthcare platform MediBuddy has collaborated with news website The Quint to raise awareness about polycystic ovarian disease (PCOD) and polycystic ovarian syndrome (PCOS).

In India, one in every 10 women suffer from PCOD and PCOS, and there still continues to remain a lack of general awareness about the ailments as they often go undetected.

MediBuddy with its campaign urges women to seek professional medical attention and lead a desired healthy lifestyle. The platform aims to debunk myths and stigma revolving around the disease.

As per data, most women on the healthcare platform sought medical consultations related to menstruation problems. About 21.27 per cent of women complained of irregular menstrual cycle and 19.7 per cent reported missed periods.

The digital healthcare platform enables individuals to seek medical help at their convenience and comfort. (ANI)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting